

Agomab is verhuisd!

"Agomab heeft een grote sprong gemaakt en heeft een spiksplinternieuw hoofdkantoor! In lijn met de exponentiële groei van onze organisatie, hebben we afscheid genomen van onze vertrouwde flexibele kantoorruimte bij Spaces in Antwerpen en zijn we verhuisd naar ons eigen, op maat gemaakte kantoor.

Bij de keuze van onze nieuwe thuisbasis hebben we zorgvuldig gekeken naar de locatie en bereikbaarheid. Ons kantoor bevindt zich naast het treinstation van Berchem in Antwerpen, waardoor het gemakkelijk toegankelijk is. Dit is belangrijk omdat ons team niet alleen uit Belgische collega's bestaat, maar ook uit talenten uit Nederland, Frankrijk, Spanje en Italië.

Ons nieuwe kantoor is een bruisende ontmoetingsplek waar iedereen graag samenkomt om de ambitieuze doelen van Agomab te realiseren," aldus Mirjam Bollema, Head of People, van Agomab. "Later deze zomer zal de oppervlakte van ons kantoor verder verdubbelen, waardoor we nog meer ruimte hebben om te innoveren en samen te groeien."

Agomab ontwikkelt potentiële behandelingen om de orgaanfunctie bij fibrotische ziekten te behouden en te herstellen. Met onze diepgaande expertise in de biologie van groeifactoren, zijn we pioniers in het ontwikkelen van nieuwe therapieën die gericht zijn op het oplossen van fibrose, het herstellen van weefselstructuren en het verbeteren van de orgaanfunctie. Onze innovatieve wetenschap wordt gecombineerd met een gedurfde bedrijfsstrategie, gericht op het ontwikkelen van een uitgebreid scala aan geneesmiddelen die zich richten op twee cruciale signaalroutes bij fibrose: transformerende groeifactor bèta (TGFβ) en hepatocytgroeifactor (HGF). AGMB-129, ons meest geavanceerde product, bevindt zich in een Fase 2a klinische studie in patiënten met de Ziekte van Crohn.

Dankzij onze serie C-financiering van \$100m in het najaar van 2023 hebben we de mogelijkheid om verder te groeien en zijn we vastbesloten om onze missie voort te zetten en te blijven streven naar medische doorbraken die een verschil maken in de wereld."



Handen uit de mouwen bij de verhuizing van Agomab

AGOMAB

Allegría Therapeutics - redefining the treatment landscape of therapeutics for mast cell-mediated diseases

Allegría Therapeutics raised a Seed Financing of USD 3.5 Million by founding investor Forty51 Ventures to advance pipeline of novel and selective therapeutic approaches for mast cell-mediated diseases.

Furthermore, the company announced the appointment of co-founder Maria van Dongen as Chief Executive Officer. Dr. Van Dongen brings broad industry experience with a strong track record in Pharma. She previously held positions at amongst others Johnson & Johnson, where she facilitated external partnerships aiming at e.g., the effective targeting of RNA processing and the discovery of peptide-based therapeutics. Previously, she led numerous R&D projects that included the discovery of highly innovative orally active broad-spectrum influenza antivirals, and an R&D platform dedicated to pharmaceutical interventions for disease prevention.

ALLEGRIA's R&D activities focus on mast cells as mediators of allergy and inflammatory diseases, a class of indications that constitutes an increasing burden world-wide.

More and more patients suffer from the impact that these conditions have on their quality of life. The associated socioeconomic burden is huge, and despite the growing medical need, the therapeutic treatment options are still notoriously limited with overall poor outcome.

With the current financing, ALLEGRIA will progress a differentiated portfolio of proprietary therapeutic approaches around targets that selectively modulate mast cells to more effectively address patients' needs.

ALLEGRIA collaborates with world leading partners in fundamental mast cell biology, drug discovery and preclinical drug evaluation including Prof. Marcus Maurer, Managing Director of the Institute for Allergy Research at Berlin's Charité and Dr. Philipp Starkl, Principal Investigator at the Medical University of Vienna.

ABOUT ALLEGRIA THERAPEUTICS

Allegría Therapeutics was founded in Basel, Switzerland by Forty51 Ventures in 2023. Pursuing a differentiated portfolio of proprietary therapeutic approaches around biological targets that selectively modulate mast cells, Allegría plans to redefine the treatment landscape for allergy and mast cell-mediated inflammatory diseases. For more information, please visit www.allegriatx.com



Igniting Leadership: Fueling First-Time CEOs to Transform Healthcare

Our industry celebrates the exceptional leadership of Hanne Callewaert, CEO of AstriVax and recipient of a 2024 Termeer Fellowship. This prestigious award from the Termeer Foundation acknowledges Hanne's impactful leadership and innovative approach in the field. With a rich background spanning over 20 years, including significant roles in both large pharmaceutical companies and biotech startups, Hanne has skillfully driven AstriVax from inception through critical stages of novel vaccine development across an array of indications of significant unmet need.



Hanne Callewaert

This recognition echoes the imperative across our industry to elevate first-time CEOs from underrepresented groups. To that end, the Termeer Foundation is dedicated to fostering new leadership in healthcare innovation by providing invaluable mentorship and networking opportunities – setting a platform for visionary leaders like Hanne to excel. Hanne shares, "Bringing treatments to patients is ambitious, hard, and challenging work. As a Termeer Fellow, I can tap into a global network of incredible healthcare leaders and boost my personal growth as CEO, as I continue my mission to improve people's lives with groundbreaking vaccines."

Further underscoring the value of this mission is Eline van Beest, former recipient of a Termeer award in 2021. Eline, who previously founded and led sleep apnea company NightBalance to a successful exit to Philips in 2018, now leads Hybridize Therapeutics and contributes as a venture partner at Thuja Capital, board member at the Netherlands Academy of Engineering, and investment committee member at InvestNL. Eline's journey through pioneering leadership roles exemplifies the powerful influence of nurturing top-tier first-time CEOs. Thuja Capital takes immense pride in backing trailblazing leaders like Hanne and Eline. As staunch supporters of first-time female CEOs in European BioTech and MedTech, Thuja is committed to fostering a diverse leadership landscape that propels the industry forward with innovative solutions to the world's most pressing healthcare problems.

Powered by:

